Syngene and VivaMed collaborate on therapeutic applications
Syngene Worldwide has entered right into a strategic partnership with VivaMed BioPharma to advance AI-based repurposed therapeutic applications.
This partnership goals to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership applications and facilitate the supply of scientifically validated, partner-ready therapeutic candidates.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
It’ll mix Syngene’s preclinical improvement experience with VivaMed’s AI-generated therapeutic hypotheses. This integration creates a pathway from computational drug candidates to translational validation.
VivaMed’s technique is constructed round three pillars. The primary pillar is AI-powered discovery, which makes use of an AI engine and a world community of co-scientists to establish biomarkers, multi-omic datasets, repurposing alternatives, and drug hyperlinks.
The second pillar is rigorous validation, supported by Syngene Worldwide. This focuses on a number of elements comparable to in vitro and in vivo pharmacological research, mechanistic pathway interrogation and assay improvement. This framework improves mental property improvement, regulatory readiness, and reproducibility.
Lastly, strategic commercialization ensures that validated applications meet pharmaceutical priorities by means of 505(b)(2) pathways and biomarker-driven methods for risk-free scale-up.
Kendric Speagle, CEO of VivaMed BioPharma, stated: “AI-driven discovery have to be accompanied by rigorous experimental execution. Our collaboration with Syngene strengthens our validation engine and ensures that our most promising applications are developed with the scientific depth and operational rigor required for pharmaceutical collaboration.”
Syngene senior vice chairman and head of strategic partnerships Kenneth Barr stated: “This partnership strengthens our capacity to use a scaled drug improvement mannequin to repurposed property, translating high-throughput analysis into credible therapeutic candidates for the last word good thing about sufferers.”
The partnership aligns with VivaMed’s broader initiative to construct a globally built-in, AI-driven drug improvement ecosystem. By bringing collectively computational prioritization and contract analysis validation experience, each firms goal to create a scalable infrastructure that allows constant, collaborative outcomes.
VivaMed continues to have interaction tutorial establishments, pharmaceutical companions and contract analysis organizations (CRO) to ship validated applications with IP safety.
